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The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose 
from a history of CV safety concerns brought to a head by findings with rosiglitazone and the 
ACCORD trial of intensive glycaemic control [1-4].  The guidance focussed mostly on pre-approval 
(phase 2 and 3) trials, recommending inclusion of sufficient patients at higher risk of CV events to 
support an analysis that could exclude an unacceptable increase in CV risk.  The analysis required a 
risk ratio with an upper bound of a two-sided 95% confidence interval (95% CI) <1.8 and preferably 
<1.3.  Post-marketing trials to assess major adverse cardiac events (MACE) might then be requested 
to confirm an upper 95% CI <1.3 using a composite 3-point MACE (CV death, nonfatal MI and 
nonfatal stroke) or 4-point MACE (3-point + hospitalisation for unstable angina) in a large population 
of type 2 diabetes patients exhibiting a range of CV disease and/or CV risk.    
Despite no increase in MACE during pre-approval phase 2/3 trials, post-marketing CV outcome trials 
(CVOTs) have been undertaken for all non-insulin glucose-lowering agents approved by FDA since 
2008.  These have confirmed a non-inferior MACE or beneficial effects on MACE compared to 
placebo when added to standard care.  FDA is now reconsidering the 2008 guidance, and McGuire et 
al provide a thoughtful and constructive evaluation of lessons learned and possible modifications to 
this guidance in their opinion article “FDA guidance on antihyperglycemic therapies for type 2 
diabetes: one decade later” [2, 5].         
The main message from the deliberations of McGuire et al is that the CVOTs have provided such 
valuable information regarding CV outcomes and other aspects of safety and efficacy that regulators 
are encouraged to retain one large randomised controlled trial (RCT) for outcomes with each new 
glucose-lowering therapy.  Given the inordinate cost of such trials (probably 200-500 million USD per 
trial), which might deter pharma enthusiasm to develop new glucose-lowering agents, the authors 
have considered potential ways to “refine” the trials to improve efficiency while increasing the 
amount, reliability and applicability of the data gathered.   
Alternative sources of relevant information from observational ‘real world’ database interrogations 
are accepted as useful complementary approaches but lacking sufficient specificity to replace large 
well-structured RCTs.  Achieving efficiency gains in RCTs might involve procedural elements such as 
simplification of re-consenting and adjudication protocols, and adopting the principles of ‘pragmatic’ 
designs could facilitate expansion of population size [6].  While active comparator trials, possibly 
with relaxed non-inferiority margins, are informative, they are not seen as alternatives to individual 
RCTs, provided that ethical aspects are fully addressed through diligent standard of care.  Also, the 
structure-function specificities of individual agents preclude generalisations across a class.   
So, the perennial problem of comparing between trials remains: higher event rates with patients 
who have already had a CV event enable shorter trials with fewer patients, but debate continues 
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over the extrapolation of safety data for secondary prevention of MACE to primary prevention in 
patients with varying degrees of CV risk [7-9].  One suggestion by McGuire et al is to define a 
minimum degree of CV risk at recruitment: other possibilities include a broader composite primary 
endpoint or multiple primary endpoints, which might then include hospitalisation for heart failure or 
all-cause hospitalisation.  However, standardising the implementation of protocols and criteria for an 
expanded range of less specific events can be a particular challenge.  Dilution of statistical power by 
multiple and hierarchical analyses with nominal significances requires careful evaluation: indeed, 
marginal differences in the upper 95% CI either side of unity have caused considerable discrepancies 
of interpretation between some CVOTs [9]. The possibility of supplementing outcomes with 
recurrent events in the same individual highlights the potential for bias, reminding that RCTs can 
reduce but not exclude susceptibility to bias and confounding variability.  
Building on the risk-benefit insights already gained from CVOTs, McGuire et al champion the 
retention of at least one large randomised outcomes trial for new glucose-lowering agents, and 
critique a selection of options for potential cost-savings and enhanced data acquisitions that 
regulators might wish to consider.        
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